NCT07114627View on ClinicalTrials.gov

Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Solid CancerGastric (Cardia, Body) CancerEsophageal CancerColorectal Cancer (CRC)
Interventions
DRUG

Blood sampling for pharmacokinetics

Extra blood samples are collected for assement of the pharmacokinetics of capecitabine.

Trial Locations (1)

3015GD

RECRUITING

Erasmus MC Cancer Institute, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT07114627 - Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients | Biotech Hunter | Biotech Hunter